North America Heart Transplant Market
The North America heart transplant market is expected to grow from US$ 7,252.10 million in 2022 to US$ 17,192.72 million by 2030. It is estimated to grow at a CAGR of 11.4% from 2022 to 2030.
A uniquely designed system backed by artificial intelligence (AI) facilitates the detection of early signs and seriousness of the host rejection post-heart transplantation. The endomyocardial biopsy (EMB) screening signifies the standard of care for identifying allograft rejections after a heart transplant. In 2022, a new AI system was designed known as the Cardiac Rejection Assessment Neural Estimator (CRANE), which can be used in tandem with medical assessments for rapid and precise diagnosis. CRANE also helps reduce differences regarding the presence and severity of heart rejection in the host body. It is a deep learning-based AI system for the automated assessment of gigapixel whole-slide images obtained from EMBs. In 2020, the National Institute of Health granted US$ 3.2 million to studies based on the exploration of the capabilities of AI in heart transplants. With this grant, researchers from Perelman School of Medicine (the University of Pennsylvania), Case Western Reserve University, Cleveland Clinic, and Cedars-Sinai Medical Center aimed to study what causes the rejection of a new heart and how to manage it. They used AI to analyze cardiac biopsy tissue images, finding the types of immune cells that play an instrumental role in new heart rejection. Thus, the adoption of AI in heart transplantation procedures is likely to bring new trends in the market in the coming years.
The heart transplant market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest market share in 2022, and the market growth can be attributed to an upsurge in the geriatric population, the prevalence of cardiovascular diseases, and an increase in heart failure cases. The increasing incidences of chronic kidney diseases and the rising geriatric population are the key factors contributing to the heart transplant market growth in the US. According to data provided by the American Heart Association Inc., ~1 million new heart failure cases are registered annually in the US, and more than 8 million people are estimated to suffer from heart failure by 2030. As per the Health Research Funding Organization, ~555,000 people were diagnosed with the beginning stages of heart failure in the US in 2021. Cardiovascular diseases (CVDs) generally lead to heart failure or terminal heart disease, which bolsters the demand for heart transplants.
The US Food and Drug Administration (FDA) is increasingly approving various heart transplant procedures and products. In addition, the presence of major companies benefits the market in this country. In April 2022, TransMedics Group, Inc. received premarket FDA approval for its OCS Heart.
Strategic insights for the North America Heart Transplant provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 7,252.10 Million |
| Market Size by 2030 | US$ 17,192.72 Million |
| Global CAGR (2022 - 2030) | 11.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Surgery Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Heart Transplant refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America heart transplant market is segmented into surgery type, type, end user, and country.
Based on surgery type, the North America heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart transplantation segment held a larger share of the North America heart transplant market in 2022.
In terms of type, the North America heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held a larger share of the North America heart transplant market in 2022. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.
Based on end user, the North America heart transplant market is segmented into hospitals, cardiac centers, and others. The hospitals segment held the largest share of the North America heart transplant market in 2022.
Based on country, the North America heart transplant market is segmented into the US, Canada, and Mexico. The US dominated the North America heart transplant market in 2022.
Terumo Corp, Evaheart Inc, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, Berlin Heart GmbH, LivaNova Plc, Jarvik Heart Inc, and Calon Cardio-Technology Ltd are some of the leading companies operating in the North America heart transplant market.
1. Terumo Corp
2. Evaheart Inc
3. Abbott Laboratories
4. SynCardia Systems LLC
5. BiVACOR Inc
6. BioVentrix Inc
7. Berlin Heart GmbH
8. LivaNova Plc
9. Jarvik Heart Inc
The North America Heart Transplant Market is valued at US$ 7,252.10 Million in 2022, it is projected to reach US$ 17,192.72 Million by 2030.
As per our report North America Heart Transplant Market, the market size is valued at US$ 7,252.10 Million in 2022, projecting it to reach US$ 17,192.72 Million by 2030. This translates to a CAGR of approximately 11.4% during the forecast period.
The North America Heart Transplant Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Heart Transplant Market report:
The North America Heart Transplant Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Heart Transplant Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Heart Transplant Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Heart Transplant Market
